Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CRG-522
- Development stage
- Unknown
- Lead developer
- CorreGene
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CRG-522 is a T-cell receptor (TCR) bispecific antibody developed by CorreGene, designed to target the Melanoma-Associated Antigen A1 (MAGE-A1) peptide-HLA complex on tumor cells. MAGE-A1 is a cancer-testis antigen frequently overexpressed in various solid tumors but absent in normal adult tissues (except testis), making it an ideal target for immunotherapy. The molecule typically consists of a high-affinity TCR domain that recognizes the MAGE-A1/HLA-A*01 complex and an anti-CD3 scFv domain that recruits and activates T cells to eliminate the target cancer cells. It is currently being evaluated in Phase 1 clinical trials for the treatment of multiple advanced solid tumors.
- Other names
- CorreGene MAGE-A1 TCR bispecific antibodyMAGE-A1 TCR bispecific antibodyMAGE-A-1 TCR bispecific antibodyMAGE-A 1 TCR bispecific antibody
02
Targets
MAGEA1 (Melanoma-associated antigen 1)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on CRG-522.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CRG-522.